Get your full text copy in PDF
Łukasz Masior, Michał Grąt, Karolina Grąt, Maciej Krasnodębski, Karolina M. Wronka, Jan Stypułkowski, Waldemar Patkowski, Mariusz Frączek, Marek Krawczyk, Krzysztof Zieniewicz
(Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland)
Ann Transplant 2020; 25:e923665
The impact of packed red blood cells (PRBCs) and fresh frozen plasma (FFP) transfusions in patients with hepatocellular cancer (HCC) undergoing liver transplantation has rarely been evaluated. The aim of the current study was to assess the impact of intraoperative transfusions on posttransplant outcomes.
MATERIAL AND METHODS: This retrospective cohort study was based on 229 HCC transplant recipients. The primary outcome measure was 5-year recurrence-free survival. Secondary outcome measures comprised overall and long-term survival at 5 years and 90-day mortality. Cox proportional hazard models and logistic regression were used to assess risk factors.
RESULTS: After adjustment for potential confounders, no association was found with respect to tumor recurrence for PRBCs (P=0.368) or FFP (P=0.081) transfusions. Similarly, PRBC transfusion (P=0.623) and FFP transfusion (P=0.460) had no impact on survival between 90 days and 5 years. PRBC transfusion increased the risk of 90-day mortality (P=0.005), while FFP transfusion was associated with a lower risk (P=0.036).
CONCLUSIONS: Intraoperative transfusions of blood products does not impair recurrence-free and long-term survival of patients with HCC undergoing liver transplantation. Intraoperative PRBC transfusion increases the risk of early mortality, whereas adequate supplementation of FFP plays a protective role.